Vivos Begins IsoPet Shipments from New U.S. Plant, Wins India Nuclear Approval
RDGL sits 19% above its 52-week low of $0.048 on light trading volume (0.1× avg).
Summary
Vivos has started shipping IsoPet from its new in-house U.S. production facility in Richland, WA, and received authorization from India's AERB to establish an international manufacturing center. These milestones give the company dual-site production for the first time, reducing reliance on third-party manufacturers and expanding global reach. The India facility will serve Asia, Middle East, and Africa markets with a 7.5-hour air transit window. This follows the FDA IDE approval in July 2026 and the ongoing HCG Cancer Centre study in India. The company's Q2 10-Q showed a going concern warning and $2.0 million net loss, so operational progress is critical for its viability.
At the time of this announcement, RDGL was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $28.3M. The 52-week trading range was $0.05 to $0.12. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.